206 related articles for article (PubMed ID: 9506325)
1. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.
Hager WD; Davis BR; Riba A; Moye LA; Wun CC; Rouleau JL; Lamas GA; Pfeffer MA
Am Heart J; 1998 Mar; 135(3):406-13. PubMed ID: 9506325
[TBL] [Abstract][Full Text] [Related]
2. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
[TBL] [Abstract][Full Text] [Related]
3. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
Pfeffer MA; Braunwald E; Moyé LA; Basta L; Brown EJ; Cuddy TE; Davis BR; Geltman EM; Goldman S; Flaker GC
N Engl J Med; 1992 Sep; 327(10):669-77. PubMed ID: 1386652
[TBL] [Abstract][Full Text] [Related]
4. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
[TBL] [Abstract][Full Text] [Related]
5. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
6. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM;
N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
[TBL] [Abstract][Full Text] [Related]
8. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.
Lamas GA; Flaker GC; Mitchell G; Smith SC; Gersh BJ; Wun CC; Moyé L; Rouleau JL; Rutherford JD; Pfeffer MA
Circulation; 1995 Sep; 92(5):1101-9. PubMed ID: 7648653
[TBL] [Abstract][Full Text] [Related]
9. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement.
Mitchell GF; Moyé LA; Braunwald E; Rouleau JL; Bernstein V; Geltman EM; Flaker GC; Pfeffer MA
Circulation; 1997 Dec; 96(12):4254-60. PubMed ID: 9416890
[TBL] [Abstract][Full Text] [Related]
10. [Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
Pfeffer MA; Braunvald Iu; Moĭe LA; Basta L; Braun EDzh ; Kaddi TE; Dévis BR; Geltman EM; Goldman S; Fleĭker GS
Kardiologiia; 1993; 33(12):14-23, 3. PubMed ID: 7910865
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
[TBL] [Abstract][Full Text] [Related]
12. Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular performance.
Kyriakidis M; Antonopoulos A; Georgiou E; Santas P; Bakirtzis C; Toutouzas P
Eur Heart J; 1996 Jun; 17(6):864-73. PubMed ID: 8781825
[TBL] [Abstract][Full Text] [Related]
13. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.
Rutherford JD; Pfeffer MA; Moyé LA; Davis BR; Flaker GC; Kowey PR; Lamas GA; Miller HS; Packer M; Rouleau JL
Circulation; 1994 Oct; 90(4):1731-8. PubMed ID: 7923656
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
15. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
[TBL] [Abstract][Full Text] [Related]
16. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
[TBL] [Abstract][Full Text] [Related]
17. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4).
Borghi C; Ambrosioni E; Novo S; Vinereanu D; Ambrosio G;
Clin Cardiol; 2012; 35(7):416-23. PubMed ID: 22707187
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
[TBL] [Abstract][Full Text] [Related]
19. Practical algorithms for pharmacologic management of the post myocardial infarction patient.
Reiffel JA; ;
Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I28-37. PubMed ID: 16450810
[TBL] [Abstract][Full Text] [Related]
20. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.
St John Sutton M; Pfeffer MA; Plappert T; Rouleau JL; Moyé LA; Dagenais GR; Lamas GA; Klein M; Sussex B; Goldman S
Circulation; 1994 Jan; 89(1):68-75. PubMed ID: 8281697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
